The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma
Open accessAbstract
The combination of temsirolimus (TEM), an MTOR inhibitor, and hydroxychloroquine (HCQ), an autophagy inhibitor, augments cell death in preclinical models. This phase 1 dose-escalation study evaluated the maximum tolerated dose (MTD), safety, preliminary activity, pharmacokinetics, and pharmacodynamics of HCQ in combination with TEM in cancer patients. In the dose escalation portion, 27 patients with advanced solid malignancies were enrolled, followed by a cohort expansion at the top dose level in 12 patients with metastatic melanoma. The combination of HCQ and TEM was well tolerated, and grade 3 or 4 toxicity was limited to anorexia (7%), fatigue (7%), and nausea (7%). An MTD was not reached for HCQ, and the recommended phase II dose was HCQ 600 mg twice daily in combination with TEM 25 mg weekly. Other common grade 1 or 2 toxicities included fatigue, anorexia, nausea, stomatitis, rash, and weight loss. No responses were observed; however, 14/21 (67%) patients in the dose escalation and 14/19 (74%) patients with melanoma achieved stable disease. The median progression-free survival in 13 melanoma patients treated with HCQ 1200mg/d in combination with TEM was 3.5 mo. Novel 18-fluorodeoxyglucose positron emission tomography (FDG-PET) measurements predicted clinical outcome and provided further evidence that the addition of HCQ to TEM produced metabolic stress on tumors in patients that experienced clinical benefit. Pharmacodynamic evidence of autophagy inhibition was evident in serial PBMC and tumor biopsies only in patients treated with 1200 mg daily HCQ. This study indicates that TEM and HCQ is safe and tolerable, modulates autophagy in patients, and has significant antitumor activity. Further studies combining MTOR and autophagy inhibitors in cancer patients are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
ULK-Atg13-FIP200 Complexes Mediate mTOR Signaling to the Autophagy Machinery
Jung, C. H., Jun, C. B., Ro, S.-H., Kim, Y.-M., Otto, N. M., Cao, J., Kundu, M., & Kim, D.-H. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-12-1249 · Cited by 2,025
Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis
Degenhardt, K., Mathew, R., Beaudoin, B., Bray, K., Anderson, D., Chen, G., Mukherjee, C., Shi, Y., Gélinas, C., Fan, Y., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.06.001 · Cited by 2,011
Deconvoluting the context-dependent role for autophagy in cancer
White, E. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3262 · Cited by 1,704
Autophagy modulation as a potential therapeutic target for diverse diseases
Rubinsztein, D. C., Codogno, P., & Levine, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3802 · Cited by 1,437
Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma
Amaravadi, R. K., Yu, D., Lum, J. J., Bui, T., Christophorou, M. A., Evan, G. I., Thomas-Tikhonenko, A., & Thompson, C. B. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28833 · Cited by 1,137
Self-citationRapamycin passes the torch: a new generation of mTOR inhibitors
Benjamin, D., Colombi, M., Moroni, C., & Hall, M. N. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3531 · Cited by 989
Principles and Current Strategies for Targeting Autophagy for Cancer Treatment
Amaravadi, R. K., Lippincott-Schwartz, J., Yin, X.-M., Weiss, W. A., Takebe, N., Timmer, W., DiPaola, R. S., Lotze, M. T., & White, E. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2634 · Cited by 897
Self-citationRosenfeld, M. R., Ye, X., Supko, J. G., Desideri, S., Grossman, S. A., Brem, S., Mikkelson, T., Wang, D., Chang, Y. C., Hu, J., et al. (2014) · Autophagy · doi:10.4161/auto.28984 · Cited by 515
Self-citationMcAfee, Q., Zhang, Z., Samanta, A., Levi, S. M., Ma, X.-H., Piao, S., Lynch, J. P., Uehara, T., Sepulveda, A. R., Davis, L. E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118193109 · Cited by 422
Self-citationVogl, D. T., Stadtmauer, E. A., Tan, K.-S., Heitjan, D. F., Davis, L. E., Pontiggia, L., Rangwala, R., Piao, S., Chang, Y. C., Scott, E. C., et al. (2014) · Autophagy · doi:10.4161/auto.29264 · Cited by 368
Self-citationRangwala, R., Leone, R., Chang, Y. C., Fecher, L. A., Schuchter, L. M., Kramer, A., Tan, K.-S., Heitjan, D. F., Rodgers, G., Gallagher, M., et al. (2014) · Autophagy · doi:10.4161/auto.29118 · Cited by 367
Self-citationAkt and Autophagy Cooperate to Promote Survival of Drug-Resistant Glioma
Fan, Q.-W., Cheng, C., Hackett, C., Feldman, M., Houseman, B. T., Nicolaides, T., Haas-Kogan, D., James, C. D., Oakes, S. A., Debnath, J., et al. (2010) · Science Signaling · doi:10.1126/scisignal.2001017 · Cited by 295
Mahalingam, D., Mita, M., Sarantopoulos, J., Wood, L., Amaravadi, R. K., Davis, L. E., Mita, A. C., Curiel, T. J., Espitia, C. M., Nawrocki, S. T., et al. (2014) · Autophagy · doi:10.4161/auto.29231 · Cited by 285
Self-citationHydroxychloroquine concentration–response relationships in patients with rheumatoid arthritis
Munster, T., Gibbs, J. P., Shen, D., Baethge, B. A., Botstein, G. R., Caldwell, J., Dietz, F., Ettlinger, R., Golden, H. E., Lindsley, H., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10307 · Cited by 249
CCI‐779 in metastatic melanoma: A Phase II trial of the California Cancer Consortium
Margolin, K., Longmate, J., Baratta, T., Synold, T., Christensen, S., Weber, J., Gajewski, T., Quirt, I., & Doroshow, J. H. (2005) · Cancer · doi:10.1002/cncr.21265 · Cited by 227
Targeting PI3 Kinase/AKT/mTOR Signaling in Cancer
Sheppard, K., Kinross, K. M., Solomon, B., Pearson, R. B., & Phillips, W. A. (2012) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v17.i1.60 · Cited by 225
Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials
Lin, Y. (2001) · Biostatistics · doi:10.1093/biostatistics/2.2.203 · Cited by 171
Barnard, R. A., Wittenburg, L. A., Amaravadi, R. K., Gustafson, D. L., Thorburn, A., & Thamm, D. H. (2014) · Autophagy · doi:10.4161/auto.29165 · Cited by 162
Self-citationAutophagy Suppresses RIP Kinase-Dependent Necrosis Enabling Survival to mTOR Inhibition
Bray, K., Mathew, R., Lau, A., Kamphorst, J. J., Fan, J., Chen, J., Chen, H.-Y., Ghavami, A., Stein, M. N., DiPaola, R. S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041831 · Cited by 159
Coordinate Autophagy and mTOR Pathway Inhibition Enhances Cell Death in Melanoma
Xie, X., White, E. P., & Mehnert, J. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055096 · Cited by 150
Oh, J.-R., Seo, J.-H., Chong, A., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2059-7 · Cited by 112
Mirzoeva, O. K., Hann, B. C., Hom, Y. K., Debnath, J., Aftab, D. T., Shokat, K. M., & Korn, W. M. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0774-y · Cited by 102
Automatic volume delineation in oncological PET
Hofheinz, F., Pötzsch, C., Oehme, L., Beuthien‐Baumann, B., Steinbach, J., Kotzerke, J., & van den Hoff, J. (2011) · Nuklearmedizin - NuclearMedicine · doi:10.3413/nukmed-0419-11-07 · Cited by 91
Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma
Davies, M. A., Fox, P. S., Papadopoulos, N. E., Bedikian, A. Y., Hwu, W., Lazar, A. J., Prieto, V. G., Culotta, K. S., Madden, T. L., Xu, Q. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2436 · Cited by 54
Temsirolimus: a safety and efficacy review
Bukowski, R. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.713344 · Cited by 42
Kwee, T. C., Torigian, D. A., & Alavi, A. A. (2012) · Journal of Thoracic Imaging · doi:10.1097/rti.0b013e31827882d9 · Cited by 23
Self-citation
Cited by
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
Levy, J. M. M., Towers, C. G., & Thorburn, A. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.53 · Cited by 2,526
Mechanisms of action of hydroxychloroquine and chloroquine:implications for rheumatology
Schrezenmeier, E., & Dörner, T. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0372-x · Cited by 1,468
Autophagy in malignant transformation and cancer progression
Galluzzi, L., Pietrocola, F., Bravo‐San Pedro, J. M., Amaravadi, R. K., Baehrecke, E. H., Cecconi, F., Codogno, P., Debnath, J., Gewirtz, D. A., Karantza, V., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201490784 · Cited by 1,182
Self-citationmTOR as a central hub of nutrient signalling and cell growth
Kim, J., & Guan, K.-L. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0205-1 · Cited by 1,072
Metadata
- Authors
- Rangwala, R., Chang, Y. C., Hu, J., Algazy, K. M., Evans, T. L., Fecher, L. A., Schuchter, L. M., Torigian, D. A., Panosian, J. T., Troxel, A. B., Tan, K.-S., Heitjan, D. F., DeMichele, A. M., Vaughn, D. J., Redlinger, M., Alavi, A., Kaiser, J., Pontiggia, L., Davis, L. E., O’Dwyer, P. J., & Amaravadi, R. K.
- Venue
- Autophagy
- Publisher
- Informa UK Limited
- Published
- 2014-05-20
- Volume
- 10
- Issue
- 8
- Pages
- 1391-1402
- ISSN
- 1554-8627 (ISSN-L)
- 1554-8635
- OpenAlex
- W1982513324
- Cited by
- 424
- References
- 29
- FWCI
- 33.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.